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Theglycoalkaloidtomatine,derivedfromthewildtomato,canactasapowerfuladjuvanttoelicitanantigen-speciﬁccell-mediated
immune response to the circumsporozoite (CS) protein, a major pre-erythrocytic stage malaria vaccine candidate antigen. Using
a deﬁned MHC-class-I-restricted CS epitope in a Plasmodium berghei rodent model, antigen-speciﬁc cytotoxic T lymphocyte
activity and IFN-γ secretion ex vivo were both signiﬁcantly enhanced compared to responses detected from similarly stimulated
splenocytes from naive and tomatine-saline-immunized mice. Further, through lymphocyte depletion it is demonstrated that
antigen-speciﬁc IFN-γ is produced exclusively by the CD8+ T cell subset. We conclude that the processing of the P. berghei CS
peptide as an exogenous antigen and its presentation via MHC class I molecules to CD8+ T cells leads to an immune response
that is an in vitro correlate of protection against pre-erythrocytic malaria. Further characterization of tomatine as an adjuvant in
malaria vaccine development is indicated.
1.Introduction
Adjuvants are immunogenic compounds that, when com-
bined with an antigen, potentiate an antigen-speciﬁc
immune response. Adjuvants may not only boost the
response of an immunologically weak antigen but also
inﬂuence the type of immune response elicited [1]. While it
has been know for many years that formulating antigen(s)
with adjuvants may potentiate the magnitude of vaccine-
elicited immune response, traditionally accepted adjuvants
such as alum and various oil-in-water emulsions have failed
toinducecytotoxicTlymphocyte(CTL)responses.However,
the ability of new generation adjuvants to deliver soluble
protein to the major histocompatibility complex (MHC)
class I processing pathway, thereby inducing antigen-speciﬁc
CTL responses, has been recognized recently [1, 2]. The
development of tomatine as an immunostimulating agent
was initiated as a direct response to the hypothesis that
reagents that were capable of delivering soluble protein
into the class I pathway would induce antigen-speciﬁc CTL
responses, and thus were likely to be powerful adjuvants [3].
The adjuvant tomatine is based upon the glycoalkaloid
lycopersicon (C50H83NO21), which is derived from the
leaves and unripe fruit of the wilt-resistant wild tomato
species Lycopersicon pimpinellifolium. This compound has
been shown to have membrane-disrupting qualities [4, 5],
similar in character to that of saponins which have long
been established as potent immunostimulators [6]. In its
naturally occurring form tomatine is known to be a primary
toxicity-based plant defense mechanism against viral and
bacterial pathogens; furthermore, it prevents infestation by
arthropods and discourages ingestion (of unripe tomatoes)
by vertebrates [7]. In spite of this, tomatine is safe and
well tolerated in mice as it does not elicit haemolytic
activity, granuloma formation, or tissue damage at the site
of inoculation. However, mononuclear cells inﬁltrate within2 Journal of Biomedicine and Biotechnology
24 hours post immunization, indicating the recruitment
of immunological mediators [8]. The adjuvant-antigen
preparation consists of a colloidal suspension of solid-state
aggregates (0.1–2μm) containing the antigen, tomatine and
cholesterol [8].
The malignant tertian malaria of humans, Plasmodium
falciparum, kills 2-3 million people and causes a further
500 million clinical infections annually. Due to increased
resistance of the parasite to available drugs and of the
mosquito vector to insecticide treatment there is a pressing
need for novel control measures, one of which is an
antimalarial vaccine [9]. For prophylactic purposes, a pre-
erythrocytic vaccine is required as it aims to prevent or
reduce the acquisition of clinical infection. By prevent-
ing either invasion of hepatocytes by sporozoites or pre-
erythrocyticstagedevelopmentwithinhepatocytes,avaccine
targeting the liver would preclude both the progression
of disease, since clinical symptoms of malaria manifest
only during the subsequent erythrocytic stage, and parasite
transmission,sincenosexualstageswoulddevelop[10].This
would beneﬁt individuals who either are malaria naive or
have lost their previously acquired immunity. It would also
enhance the naturally acquired protective immune response
of individuals resident in malaria-endemic countries that is
achieveduponprolongedexposure,inordertoeitherprevent
blood stage infection or to reduce the numbers of parasites
that emerge from the liver [11].
Preclinical vaccine trials may be conducted in murine
malaria models to validate candidate antigens prior to
testing in humans. One such antigen that has been studied
extensively is the immunodominant circumsporozoite (CS)
protein that is the major surface protein of sporozoites,
the hepatocyte-invasive stage of the Plasmodium life cycle
[12]. Passive transfer of a CTL clone recognizing P. berghei
CS peptide SYIPSAEKI (aa 252–260) derived from mice
immunized with irradiated P. berghei sporozoites conferred
a high degree of protection to mice against homologous
sporozoite challenge [13]. Furthermore, vaccination with
this deﬁned P. berghei CS peptide conferred protection
against homologous challenge in mice which express MHC
class I molecules of the H2-k
d haplotype when CS peptide-
speciﬁc CD8+ T cells were elicited [14]. As both the target
antigen and the protective immune response to it in this
malariamodelarecharacterizedthisprovidesapowerfultool
for vaccinologists, as the potential of novel adjuvants to elicit
an antigen-speciﬁc MHC-class-I-restricted CTL response
may be assessed.
The objective of this study was to exploit the ability of
the novel adjuvant tomatine to potentiate a CTL response
againsttheP.bergheiCS peptide inordertoidentify cytokine
production of deﬁned lymphocyte populations. This would
have the dual eﬀect of both helping to evaluate further the
mechanism of action of tomatine as a vaccine adjuvant and
to elucidate the mechanism of protective immunity against
pre-erythrocyticmalaria.Themostsuccessfulvaccineagainst
human malaria to date, protecting six of seven volunteers,
containsregionsofCSproteinthatstimulatepeptide-speciﬁc
CD8+ T cell responsiveness [15, 16].
2.MaterialsandMethods
2.1. Preparation of Tomatine-Antigen Vaccine. Tomatine was
prepared with the P. berghei CS peptide by minutesor
modiﬁcation of a protocol described in detail previously [8,
17]. Brieﬂy, the adjuvant comprised two mixtures, A and B,
whichwereformulatedasfollows.MixtureA.25mgtomatine
(Fluka, Gillingham, UK), 125 mg octylglucopyranoside
(Sigma, Poole, UK) and 3.1mg phosphatidylethanolamine
(PE) (Fluka) were added to 4mL sterile saline, vortexed and
heated to 60◦C until a clear solution was obtained, which
was then allowed to cool to room temperature. Mixture B.
6.25mg cholesterol (Sigma), 125mg octylglucopyranoside
and 3.1mg PE were added to 3mL sterile saline, the solution
then prepared as for mixture A and allowed to cool to
37◦C. P. berghei CS peptide SYIPSAEKI (aa 252–260) was
prepared in-house by solid phase chemical synthesis and
conﬁrmed as 75% full-length product by high-performance
liquid chromatography and mass spectrophotometry. 2.5mg
peptide was dissolved in 3mL sterile saline and added to
mixture A, vortexed and incubated at 37◦Cf o r1 0m i n u t e s ,
after which mixture B was added, vortexed and incubated
at 37◦C for a further 30 minutes. After vortexing, the
completed formulation was placed at 37◦C for 24 hours
afterwhichtheresultantcloudysolutionwasdialyzedagainst
sterile saline using a 10000MW cutoﬀ membrane (Slide-
a-lyzer, Pierce, Chester, UK) to remove any unassociated
octylglucopyranoside. A tomatine-saline adjuvant control
was prepared by an identical method but without the
addition of the CS peptide.
2.2. Immunization. Three experimental groups comprised
naive mice or mice immunized with a preparation of either
tomatine-P. berghei CS peptide or tomatine-saline. BALB/c
(H2d) inbred strain mice (Harlan Olac, Bicester, UK) were
usedwhen6–8weeksold.Femalemice(fourpergroup)were
injected subcutaneously in the scruﬀ of the neck with 200μL
of the adjuvant-antigen preparation (50μg peptide/mouse)
on day 0 and then again 28 days later.
2.3. Preparation of Splenic Lymphocytes. Mice were sacriﬁced
on day 42 postprimary immunization (14 days after boost-
ing).Spleenswereasepticallyremovedandsinglecellsuspen-
sions in RPMI 1640 (Gibco, Paisley, UK) supplemented with
10% (v/v) heat-inactivated fetal bovine serum (complete
medium) prepared using a 20μms i e v ef r o me a c hm o u s e
individually as described previously [18, 19]. Erythrocytes
were lyzed with 0.17M Tris-buﬀered ammonium chloride
and membrane debris was removed by ﬁltration through
sterile gauze. Viability determined by trypan blue exclusion
was routinely >95%.
2.4. Lymphocyte Subset Depletion. Lymphocyte subset deple-
tion was performed by immunomagnetic cell sorting to
>98% purity on splenocytes from mice immunized with
tomatine-P. berghei CS peptide following ex vivo restimu-
lation with homologous peptide (25μg/mL), as previouslyJournal of Biomedicine and Biotechnology 3
Table 1: Cytolytic activity of splenocytes from mice immunized with adjuvant-antigen preparations of tomatine-P. berghei CS peptide or
tomatine-saline following ex vivo restimulation with P. berghei CS peptide (25μg/mL). Control cytolytic activity of similarly stimulated
splenocytes from naive mice is also shown. Data represent percentage speciﬁc lysis of P815 target cells loaded with P. berghei CS peptide or
withnopeptide(mediumcontrol)overarangeofeﬀector:targetcellratios.Datashownrepresentthemeanoffourmice,assayedindividually
in triplicate, from one of four similar experiments. Cytolytic activity following CS peptide stimulation (shown in bold):
∗P <. 025 versus
tomatine-saline group, P<. 05 versus naive group,
∗∗P <. 05 versus tomatine-saline group, determined by the Mann-Whitney U-test. The
positive control cytolytic T cell clone CS.C7 speciﬁc for P. berghei CS peptide elicited 81.2 and 53.0% P815 cell lysis at an eﬀector: target
ratio of 100:1 and 50:1, respectively.
Percentage target cell lysis
Eﬀector: target cell ratio Naive Tomatine saline Tomatine-CS peptide Medium
100:1 6.8 (0.9) 3.7 (0.2) 19.2 (3.6)∗ 2.5 (0.1)
50: 1 6.1 (0.3) 4.8 (0.9) 16.4 (1.4)∗ 4.3 (0.1)
25:1 5.1 (0.5) 3.0 (1.0) 9.7 (0.2)∗∗ 4.3 (0.5)
1:1 7.7 (0.8) 4.0 (0.2) 2.5 (0.8) 4.8 (0.5)
Table 2: Type 1 cytokine production by splenocytes from mice immunized with adjuvant-antigen preparations of tomatine-P. berghei CS
peptide or tomatine-saline following ex vivo restimulation with P. berghei CS peptide (25μg/mL). Control cytokine production of similarly
stimulated splenocytes from naive mice is also shown. Data represent fold increases in secretion of each cytokine over that of splenocytes
from identically immunized mice within each group but which were not restimulated ex vivo (absolute levels shown in italics). Data shown
represent the mean of four mice, assayed individually in triplicate, from one of four similar experiments. IFN-γ production (shown in bold):
∗P <. 05 versus tomatine-saline group; P<. 04 versus naive group, determined by the Mann-Whitney U-test.
Cytokine Naive Tomatine saline Tomatine-CS peptide Unstimulated cells (pg/mL)
IL-12 1.02 (0.32) 0.92 (0.44) 1.22 (0.27) 97.84 (21.22)
IFN-γ 0.88 (0.38) 1.48 (0.40) 3.48 (0.64)∗ 153.17 (32.74)
TNF-α 1.66 (0.61) 1.54 (0.41) 1.28 (0.71) 39.08 (5.61)
described [20, 21]. Lymphocytes were prepared from single-
cell suspensions of spleen cells by Ficoll gradient centrifuga-
tion (Lympholyte-Mammal; Tebu-Bio, Peterborough, UK).
Immunomagnetic cell sorting was performed for B, T, CD4+
and CD8+ T cells using Dynal mouse cell negative isolation
kits (Invitrogen, Oxford, UK), following manufacturer’s
instructionsforbinding,washingandelution.Thespeciﬁcity
of each depletion treatment was assessed by ﬂow cytometry.
Cells were incubated with rat IgG2b monoclonal antibody
(mAb) speciﬁc for murine CD20 (pan-B), CD3 (pan-
T), CD4, and CD8 (AbD Serotec, Oxford, UK). Negative
controls of cells incubated with normal rat serum in place
of a primary mAb and of untreated cells were included.
FITC-conjugated goat anti-rat IgG (Sigma) was used as
the secondary mAb. Labelled cells were analyzed on a
FACSCalibur ﬂow cytometer (Becton-Dickinson, Oxford,
UK) after correction for nonspeciﬁc ﬂuorescence of controls
and exclusion of dead cells and granulocytes on the basis of
forward and right-angle light scatter.
2.5. Measurement of Cytolytic Activity. To assay for a CTL
response, the cultured spleen cells were used as eﬀector
cells against P815 target cells labelled with 51Cr (Amersham
Int., Little Chalfont, UK). P815 cells, which express H2-k
d
molecules [13], were loaded with P. berghei CS peptide. A
cytolytic T cell clone (CS.C7) speciﬁc for this peptide [13]
was similarly assayed as a positive control. Three aliquots of
1 × 106 c e l l sw e r ee a c hl a b e l l e dw i t h1 m C i51Cr in 1mL.
Five micrograms CS peptide or 5mL saline was added to the
aliquots. The cells were then incubated for 1 hour at 37◦C,
after which they were washed twice with 10mL complete
medium. Eﬀector and target cells were incubated at ratios
of 100:1–1:1 in V-bottomed microtitre plates (Gibco) for
4 hours at 37◦C. The cells were pelleted by centrifugation
at 200 × g for 2 minutes and 100μL of the supernatant was
added to 100μL of scintillant (Optiphase HiSafe 3, Wallac,
Milton Keynes, UK) in a 96-well plate (Isoplate, Wallac),
mixed well and 51Cr activity was measured on a beta counter
(1450 Microbeta, Wallac). Cytolytic activity was calculated
using the following formula to determine target cell lysis:
%l y s i s =
(testrelease −spontaneousrelease)
(maximumrelease −spontaneousrelease)
.
2.6. In Vitro Restimulation for Cytokine Production. To gen-
erate cytokine-containing supernatants, spleen cell suspen-
sions were adjusted to a ﬁnal concentration of 5 × 106/mL
in complete medium and 100μL aliquots placed in 96-well
ﬂat-bottomtissuecultureplates(Nunc,Roskilde,Denmark),
t ow h i c hw e r ea d d e d1 0 0μL volumes of complete medium
alone,orcontainingﬁnalconcentrationsofoneofthefollow-
ing: 25μg/mL P. berghei CS peptide, 1μg/mL concanavalin A
(ConA;Sigma),25μg/mLEscherichiacolilipopolysaccharide
(LPS; Sigma) [20]. Cultures were incubated for 6 days
(37◦C, 5% CO2); supernatants were removed, centrifuged at
300 × g f o r5m i n u t e s ,a n ds t o r e da t−20◦C until assayed.
2.7.CytokineMeasurement. Levelsofthetype1cytokinesIL-
12, IFN-γ and TNF-α were quantiﬁed by two-site sandwich
enzyme-linked immunosorbent assay (ELISA) [22], using4 Journal of Biomedicine and Biotechnology
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Figure 1: IFN-γ production by splenocytes from mice immunized
with tomatine-P. berghei CS peptide following ex vivo restimula-
tion with P. berghei CS peptide (25μg/mL). Lymphocyte subset
depletion was performed by immunomagnetic cell sorting to >98%
purity. Data are fold increases in cytokine secretion over that of
splenocytes from identically immunized mice not restimulated ex
vivo (by convention, value = 1.0, depicted as a horizontal line).
Data shown represent the mean of four mice, assayed individually
in triplicate, from one of four similar experiments.
∗P <. 05 versus
other groups, determined by the one-way ANOVA test.
DuoSeT
TM matched antibodies (Genzyme, West Malling,
UK) and following manufacturer’s instructions. Reactivity
was visualised using 3,3 ,5,5 -tetramethylbenzidine (TMB)
in 0.05 M phosphate-citrate buﬀer and 0.014% (v/v)
hydrogen peroxide (Sigma) as substrate. Optical densities
were determined at 450nm using an Emax plate reader
(Molecular Devices, Crawley, UK). Recombinant murine
cytokines (Genzyme) were used for calibration. Control
samples of spleen cell culture supernatants from naive,
nonimmunized mice, derived under identical conditions
to experimental samples, showed low background cytokine
levels to speciﬁc antigen (<5ng/mL;SI  2). The minimum
level of detection for each cytokine was between 30–
60pg/mL.
3. Results
3.1. Cytolytic Activity of Splenocytes after Stimulation with P.
berghei CS Peptide. The cytolytic activity of splenocytes was
assessed by coincubation with P815 target cells loaded with
peptide. In the presence of homologous peptide (25μg/mL),
cells derived from P. berghei CS-immunized mice produced
signiﬁcantlyraisedpeptide-speciﬁcCTLactivityat100–50:1
eﬀector: target ratios compared to splenocytes from either
tomatine-saline immunized mice (P<. 025) or from naive
controls (P<. 05) (Table 1). At a 25:1 eﬀector: target
ratio peptide-speciﬁc CTL activity was signiﬁcantly greater
for splenocytes from tomatine-CS peptide-immunized mice
than for splenocytes from mice immunized with tomatine-
saline (P<. 05) but not from naive controls (P>. 05)
(Table 1).Therewasnosigniﬁcantdiﬀerencebetweengroups
at a 1:1 eﬀector: target ratio (P>. 05).
3.2. Cytokine Production from Splenocytes After Stimulation
with P. berghei CS Peptide. Following restimulation ex vivo
with P. berghei CS peptide (25μg/mL), splenocytes from
mice immunized with tomatine-CS peptide showed signif-
icantly upregulated production of IFN-γ when compared
to splenocytes from either tomatine-saline-immunized mice
(P<. 05) or from naive controls (P<. 04) (Table 2).
Production of the other type 1 cytokines measured, IL-12
and TNF-α, was similar for all three experimental groups
(P>. 05). The relatively low antigenicity of tomatine on its
own was exempliﬁed by the similar production of each of IL-
12, IFN-γ and TNF-α by splenocytes from tomatine-saline-
immunized mice compared to controls (P<. 05) (Table 2).
This therefore demonstrated the capacity of tomatine to act
as an adjuvant for delivery of P. berghei CS peptide, notably
for the induction of the pronounced production of antigen-
speciﬁc IFN-γ.
In the presence of homologous peptide (25μg/mL),
splenocytes from tomatine-CS peptide-immunized mice did
not elicit a type 2-speciﬁc cytokine proﬁle when compared
to the response of similarly stimulated splenocytes from the
adjuvant control and naive mice. IL-4 and IL-10 were mea-
sured in all supernatants but production of each was below
the level of detection of the respective ELISA. Stimulation
with the mitogens Con A or LPS induced splenocytes from
each experimental group to produce predominantly type 1
and type 2 responses, respectively, (data not shown).
3.3. IFN-γ Production by Lymphocyte Subsets After Stimu-
lation with P. berghei CS Peptide. Following restimulation
ex vivo with P. berghei CS peptide (25μg/mL), splenocytes
were depleted of B, T, CD4+ and CD8+ T cell fractions by
immunomagnetic cell sorting. In each case contamination
with residual cells was <2% of the undepleted population, as
determinedbyﬂowcytometry.Splenocytesdepletedofeither
B cells or CD4+ T cells produced similar levels of IFN-γ to
undepleted splenocytes (P>. 05). In contrast, depletion of
either T cells or the CD8+ T cell subset ablated the IFN-γ
response to the CS peptide (P<. 05) (Figure 1).
4. Discussion
The purpose of an adjuvant is to elicit an appropriate and
eﬀective immune response against the antigen(s) with which
it is administered. Protective antigens generally require a
speciﬁc type of response to be induced if the immunized
host is to combat eﬀectively a challenge infection. Studies
in various murine malaria models have shown that animals
immunized with radiation-attenuated sporozoites develop
parasite-speciﬁc CD8+ T cells and that depletion of such
cells abrogates protection [23–25]. Moreover, this has beenJournal of Biomedicine and Biotechnology 5
corroborated by the recent development of genetically-
attenuated sporozoites [26].
In the present study, immunization of mice with the
deﬁned P. berghei CS peptide SYIPSAEKI (aa 252–260)
was used to examine the capacity of the novel adjuvant
tomatine to potentiate antigen-speciﬁc cellular immune
responses to pre-erythrocytic malaria. When restimulated
with homologous peptide ex vivo, splenocytes derived from
mice immunized with the tomatine-CS peptide vaccine
elicited a peptide-speciﬁc CTL response and upregulated
production of the type 1 cytokine IFN-γ. This supported our
hypothesis that immunization with the tomatine-CS peptide
vaccine might elicit a CD8+ Tc e l lr e s p o n s ei ft h i sp e p t i d e
were presented in association with MHC class I molecules.
The pronounced production of IFN-γ by splenocytes
from tomatine-P. berghei CS peptide-immunized mice upon
CS peptide stimulation has particular signiﬁcance, since this
is recognized as a major host defence mechanism against
liver stage malaria [10, 23]. The CD8+ T cell epitope for
BALB/c mice within the P. berghei CS peptide appeared to
elicit IFN-γ production by tomatine-CS peptide-immunized
splenocytes ex vivo since when the cells were depleted of
speciﬁc lymphocyte fractions, removal of CD8+ Tc e l l s
ablated the IFN-γ response.
ThepivotalimportanceofIFN-γ totheimmuneresponse
to pre-erythrocytic malaria is well established. Recombinant
IFN-γ inhibits the in vitro development of intrahepatic
parasites[27,28],whileanti-IFN-γ mAbtreatmentabrogates
protection in mice immunized with radiation-attenuated
sporozoites [23, 29]. Administration of IFN-γ or IL-12
protects mice [27, 30] and monkeys [31, 32] against pre-
erythrocytic malaria, and in mice the protection is reduced
when the synthesis of nitric oxide (NO) is inhibited [30].
These ﬁndings suggest that CD8+ T cells may additionally
perform a noncytolytic role in this protective immunity.
Following induction by IL-12, CD8+ T cells produce IFN-
γ which stimulates the production of inducible NO that
subsequently mediates the elimination of the liver stage par-
asite[33,34].Indeed,perforin-deﬁcient,CD95-andCD95L-
mutant mice immunized with irradiation-attenuated sporo-
zoites were each shown to be protected against a P. berghei
challenge infection [35], indicating that this response alone
is protective. It is probable therefore that sensitization of
aC D 8 + T cell population to produce high levels of IFN-γ
promotes the induction of both cytolytic and noncytolytic
mechanisms of protective immunity [12, 36].
5. Conclusions
The release of IFN-γ by CD8+ T cells is considered a critical
component of immunity induced by liver stage malaria
[36], and successful vaccination of humans with vaccines
designed to elicit protective immunity will require induction
of speciﬁc CD8+ T cells that home to the liver [37]. In
this context, our ﬁndings validate the use of tomatine to
potentiate a cellular immune response to antigenic stimulus
by testing in an important biologically relevant system [38,
39]. Speciﬁcally, the processing of the P. berghei CS peptide
as an exogenous antigen and its presentation via MHC class
Im o l e c u l e st oC D 8 + T cells led to IFN-γ secretion that is
an in vitro correlate of protection against pre-erythrocytic
malaria [10, 40]. This was conﬁrmed by the protective
capacity of the tomatine-CS peptide combination upon
in vivo immunization [19]. These ﬁndings merit further
work to optimize the use of tomatine as an adjuvant in
malaria vaccine development. Future studies are required
to understand the mechanism by which tomatine generates
antigen-speciﬁc CTL when formulated with soluble protein.
In particular, the processing pathways used to load the MHC
class I molecules and which antigen-presenting cells are
involved are being investigated.
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